Global Lupus Market has been segmented into type, treatment, and end user. The global market, by types, has been segmented into systemic lupus erythematosus, cutaneous lupus erythematosus, drug-induced lupus erythematosus, and neonatal lupus. The systemic lupus erythematosus segment is expected to hold the largest market share owing to the growing prevalence and increasing drug development in recent years.
On the basis of treatment, the global market has been segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarial drugs, corticosteroids, immunosuppressants, biologics, and other.
On the basis of end user, the global market has been segmented intohospital & clinics, diagnostic laboratories, and others.
Get Sample Copy for this Report https://www.marketresearchfuture.com/sample_request/6636
Key Players
Some of the prominent players in the global lupus market are Aurinia Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Cadila Healthcare, GlaxoSmithKline plc, Mylan N.V., F. Hoffmann-La Roche AG, Pfizer, Inc., Sanofi, Lycera Corporation, Eli Lily and Company, and Merck KGaA.
The
growing prevalence of lupus, ongoing medical advancements in the treatment of
systemic lupus erythematosus, rising research and development activities are
some factors that are expected to propel the market growth during the
assessment period. On the other hand, the factors such as strict government
regulation and increasing prices of lupus drugs may hinder the market growth
over the assessment period.
Comments